Medical Devices Pipeline Assessment on Clinical Chemistry Rapid Tests and POC

December 9, 2020

Medical devices pipeline assessment on clinical chemistry rapid tests and POC report is now available through Research and Markets. This report provides comprehensive information about the Clinical Chemistry Rapid Tests & POC pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Clinical chemistry rapid tests provide the test results immediately. These tests are used in low resource settings with the help of test strips, tablets and solutions.

Scope

  • Extensive coverage of the Clinical Chemistry Rapid Tests & POC under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Clinical Chemistry Rapid Tests & POC and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Clinical Chemistry Rapid Tests & POC under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Products under Development

3.1 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Stage of Development

3.2 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Territory

3.3 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Regulatory Path

3.4 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Estimated Approval Date

3.5 Clinical Chemistry Rapid Tests & POC – Ongoing Clinical Trials

4 Clinical Chemistry Rapid Tests & POC – Pipeline Products under Development by Companies

4.1 Clinical Chemistry Rapid Tests & POC Companies – Pipeline Products by Stage of Development

4.2 Clinical Chemistry Rapid Tests & POC – Pipeline Products by Stage of Development

5 Clinical Chemistry Rapid Tests & POC Companies and Product Overview

6 Clinical Chemistry Rapid Tests & POC- Recent Developments

7 Appendix

7.1 Methodology

7.2 About the Publisher

7.3 Contact

Companies Mentioned

  • Abreos Biosciences Inc
  • Acetaminophen Toxicity Diagnostics, LLC
  • Affinergy LLC
  • Am Biotechnologies, LLC
  • AnaZyme LLC
  • Angle Biosciences Inc
  • Atonomics A/S
  • Augurix SA
  • Baebies Inc
  • Base Pair Biotechnologies Inc
  • Biocross SL
  • Bioftalmik Applied Research
  • Biotech Resources Aust Pty Ltd
  • Boditech Med Inc
  • Burnet Institute
  • Carclo Diagnostic Solutions Ltd
  • CardioGenics Inc
  • Cellex Inc
  • Center for Biomedical Research Network in Bioengineering, Biomaterials and Nanomedicine
  • Claremont BioSolutions
  • Columbia University
  • CTK Biotech Inc
  • DiaSys Diagnostic Systems GmbH
  • Edan Instruments Inc
  • Enesi Pharma Ltd
  • Enigma Diagnostics Ltd (Inactive)
  • Erytech Pharma SA
  • FK-Biotecnologia SA
  • Foundation for Innovative New Diagnostics
  • Gendiag
  • Group K Diagnostics
  • Instrumentation Laboratory Co
  • Integrated Diagnostics Inc (Inactive)
  • IntraMed Diagnostics, LLC
  • IPI Singapore
  • Iron Horse Diagnostics, Inc.
  • Kenyatta University
  • Massachusetts Institute of Technology
  • Medical University of South Carolina
  • Monash University
  • Montana State University
  • NanoSpeed Diagnostics Inc
  • Novartis AG
  • Ohmx Corp
  • OPKO Health Inc
  • Oxford Immunotec Ltd
  • P2D Inc
  • Pennsylvania State University
  • Philips Healthcare
  • Pop Test LLC
  • PortaScience Inc
  • ProciseDx LLC
  • Quidel Corp
  • SaltCheck Inc (Inactive)
  • Seattle Children’s Hospital
  • SenGenix Inc
  • SuperNova Diagnostics, Inc.
  • Systagenix Wound Management Ltd
  • The University of New South Wales press Limited
  • Thermo Fisher Scientific Inc
  • Trivitron Healthcare Pvt Ltd
  • True Diagnostics Inc
  • Universal Biosensors Inc
  • University of Edinburgh
  • University of South Australia
  • UrSure Inc

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version